Skip to main content
Clinical Trials/EUCTR2010-023122-21-GB
EUCTR2010-023122-21-GB
Active, not recruiting
Phase 1

Pro-Bono 2- A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options: Vitamin D sub study. - Pro-Bono-2 Vitamin D SubStudy

King's College London0 sites0 target enrollmentStarted: October 10, 2011Last updated:

Overview

Phase
Phase 1
Status
Active, not recruiting

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • Aged between 18 years and 45 years , Males and Females
  • Documented Positive HIV\-1 antibody test and either stable on HAART as defined by undetectable viral load and on the same regimen for \=6 months or treatment naive (HIV\+ cohort only) (n\=32\)
  • Presumed HIV negative –(HIV negative cohort only) (n\=16\)
  • Ability to give informed consent
  • Females willing to use barrier method contraception (condoms) for the duration of the trial.
  • Documented Vitamin D deficiency (less than 50 nmol/L within 6 months of screening)
  • Not currently taking Vitamin D supplements, or has taken any Vitamin D supplements within 4 weeks of screening
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • Pregnancy or breast feeding
  • Patient unlikely to comply with protocol
  • 1Received vitamin D supplementation within the previous 4 weeks.
  • Documented history of renal impairment
  • Any chronic inflammatory condition
  • Documented Hepatitis B or C
  • Documented soya or peanut allergy or hypersensitivity to any of the constituents of Dekristol®
  • Hypercalcaemia or hypercalciuria
  • Pseudohypoparathyroidism

Investigators

Similar Trials